vesicles are engineered to enhance their natural anti-inflammatory and tissue repair properties through targeted miRNA.

Our focus addresses critical health challenges, including osteoarthritis, Alzheimer’s disease, dermatological conditions, and metabolic dirsorders. By fostering strategic collaborations with academic leaders and pharmaceutical industry partners, we have built a strong scientific foundation and a clear pathway to clinical impact.

Our platform is designed to overcome key manufacturing and delivery challenges. Innovations include: * A single cell source to minimize batch variability. * A proprietary perfused adherent bioreactor for scalable, cost-efficient production. * Exclusive nanofluidic technology for miRNA loading without altering sEV integrity.

This dual-action approach—targeting inflammation and promoting tissue regeneration—enables systemic interventions for inflammatory and degenerative diseases. Our initial proof of concept in osteoarthritis demonstrates the potential of our platform to deliver accessible, affordable, and impactful therapies.